Evidence map›Paper›PMID 33291318›Full record

ArticleInternational journal of molecular sciences2020

Dihydrotanshinone, a Natural Diterpenoid, Preserves Blood-Retinal Barrier Integrity via P2X7 Receptor.

Claudia Giuseppina Fresta, Giuseppe Caruso, Annamaria Fidilio, Chiara Bianca Maria Platania, Nicolò Musso, Filippo Caraci, Filippo Drago, Claudio Bucolo

Open access · goldAbstract read
In one paragraph

Article in International journal of molecular sciences, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed
2.9field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

21 citing papers in PubMed, 37 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Review
  7. Review
  8. Role of P2X7R in Retinal Diseases: A Review.Immunity, inflammation and disease · 2025
    Review
  9. Article
  10. Review
  11. Article
  12. Towards an Understanding of Retinal Diseases and Novel Treatment.International journal of molecular sciences · 2022
    Article
  13. Article
  14. Review
  15. Article
  16. Article
  17. Review
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Claudia Giuseppina FrestaDepartment of Biomedical and Biotechnological Sciences, School of Medicine, University of Catania, 95125 Catania, Italy.
Giuseppe CarusoDepartment of Drug Sciences, University of Catania, 95125 Catania, Italy.ORCID 0000-0003-1571-5327
Annamaria FidilioDepartment of Drug Sciences, University of Catania, 95125 Catania, Italy.
Chiara Bianca Maria PlataniaDepartment of Biomedical and Biotechnological Sciences, School of Medicine, University of Catania, 95125 Catania, Italy.
Nicolò MussoDepartment of Biomedical and Biotechnological Sciences, School of Medicine, University of Catania, 95125 Catania, Italy.ORCID 0000-0003-2451-1158
Filippo CaraciDepartment of Drug Sciences, University of Catania, 95125 Catania, Italy.ORCID 0000-0002-9867-6054
Filippo DragoDepartment of Biomedical and Biotechnological Sciences, School of Medicine, University of Catania, 95125 Catania, Italy.
Claudio BucoloDepartment of Biomedical and Biotechnological Sciences, School of Medicine, University of Catania, 95125 Catania, Italy.
University of Catania · IT

Funding

Italian Ministry of Economic Development (MISE) PON-Innovative PhD Program XXXIII E37H18000340006Ministry of Education, University and Research (MIUR) PRIN 2015JXE7E8PIACERI 2020/2022 Linea Intervento 2, University of Catania
6 · The paper itself

Abstract

Activation of P2X7 signaling, due to high glucose levels, leads to blood retinal barrier (BRB) breakdown, which is a hallmark of diabetic retinopathy (DR). Furthermore, several studies report that high glucose (HG) conditions and the related activation of the P2X7 receptor (P2X7R) lead to the over-expression of pro-inflammatory markers. In order to identify novel P2X7R antagonists, we carried out virtual screening on a focused compound dataset, including indole derivatives and natural compounds such as caffeic acid phenethyl ester derivatives, flavonoids, and diterpenoids. Molecular Mechanics/Generalized Born Surface Area (MM/GBSA) rescoring and structural fingerprint clustering of docking poses from virtual screening highlighted that the diterpenoid dihydrotanshinone (DHTS) clustered with the well-known P2X7R antagonist JNJ47965567. A human-based in vitro BRB model made of retinal pericytes, astrocytes, and endothelial cells was used to assess the potential protective effect of DHTS against HG and 2'(3')-O-(4-Benzoylbenzoyl)adenosine-5'-triphosphate (BzATP), a P2X7R agonist, insult. We found that HG/BzATP exposure generated BRB breakdown by enhancing barrier permeability (trans-endothelial electrical resistance (TEER)) and reducing the levels of ZO-1 and VE-cadherin junction proteins as well as of the Cx-43 mRNA expression levels. Furthermore, HG levels and P2X7R agonist treatment led to increased expression of pro-inflammatory mediators (TLR-4, IL-1β, IL-6, TNF-α, and IL-8) and other molecular markers (P2X7R, VEGF-A, and ICAM-1), along with enhanced production of reactive oxygen species. Treatment with DHTS preserved the BRB integrity from HG/BzATP damage. The protective effects of DHTS were also compared to the validated P2X7R antagonist, JNJ47965567. In conclusion, we provided new findings pointing out the therapeutic potential of DHTS, which is an inhibitor of P2X7R, in terms of preventing and/or counteracting the BRB dysfunctions elicited by HG conditions.

Indexed as

Adenosine TriphosphateAstrocytesBinding SitesBlood-Retinal BarrierCapillary PermeabilityCell LineConnexin 43CytokinesCytoprotectionEndothelial CellsFuransHumansPericytesPhenanthrenesProtein BindingPurinergic P2X Receptor Agonists3'-O-(4-benzoyl)benzoyladenosine 5'-triphosphateAdenosine TriphosphateConnexin 43Cytokinesdihydrotanshinone IFuransPhenanthrenesPurinergic P2X Receptor AgonistsPurinergic P2X Receptor AntagonistsQuinonesReactive Oxygen SpeciesReceptors, Purinergic P2X7blood-retinal barrierdiabetic retinopathyendothelial cellsinflammationoxidative stresspurinergic P2X7 receptor

Identifiers

PMID33291318
PMCPMC7730037
OpenAlexW3111734117

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.